New branding unifies Numinus’ presence across North America
Rebranding will be accomplished in phases and completed by end of 2022
VANCOUVER, BC, June 27, 2022 – Numinus Wellness Inc. (“Numinus”, the “Company”) (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce the launch of a new visual brand identity that will be applied to all Company assets, including its clinics, research sites and digital properties, by the end of 2022 – complementing Numinus’ continued growth as a leading mental health care company providing psychedelic-assisted therapies across North America.
“Numinus has grown significantly since our founding in 2018. Our recent expansion to the US marked a key opportunity to revitalize our brand while unifying our service offerings,” said Payton Nyquvest, Founder and CEO, Numinus. “Our new updated identity will be instrumental for Numinus as we expand our market presence, drive increased brand awareness, and, ultimately, advance as a leader in psychedelic-assisted therapy and mental health care across North America.”
The visual identity, created in partnership with leading creative agency, GrandArmy, reflects the essence of Numinus’ vision – blending the art and science of innovative mental health care through use of geometry and colour.
“As Numinus grows at a community and global level, an impactful visual identity that brings together all parts of the business will help us build stronger brand connection for both our external and internal audiences,” says Danielle Hinan, VP, Marketing, Numinus. “We underwent a rigorous rebranding exercise, exploring sacred geometry and symbolism to create a brand that is timeless and engaging, and we can’t wait to bring it to life in the coming months.”
The rebranding will be completed in a multi-phased approach, with current Numinus branded assets and websites immediately being rebranded, followed by the rebranding of subsidiaries Mindspace, the Neurology Centre of Toronto, Cedar Psychiatry, Cedar Clinical Research and Foundations for Change later in the year. Numinus expects all assets to be rebranded to showcase one unified brand by the end of 2022.
Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Neither Numinus Wellness Inc., nor any of its subsidiaries is a professional corporation licensed to practice health services. In jurisdictions where health services may only be provided by a corporation if that corporation holds a valid permit to do so, Numinus and its subsidiaries operate in a management services function to affiliated professional corporations, who provide health services to patients. Numinus and its subsidiaries do provide health services directly to patients in those jurisdictions where authorized to do so.
This news release includes certain “forward‐looking information” and “forward‐looking statements” (collectively “forward‐looking statements”) within the meaning of applicable Canadian securities legislation, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. All statements in this news release that address events or developments that the Company expects to occur in the future are forward‐looking statements. Forward‐looking statements are statements that are not historical facts and are often identified by words such as “expect”, “plan”, “anticipate”, “project”, “target”, “potential”, “schedule”, “forecast”, “budget”, “estimate”, “intend” or “believe” and similar expressions or their negative connotations, or that events or conditions “will”, “would”, “may”, “could”, “should” or “might” occur, and include information regarding expectations around the rebranding, and expectation for other economic, business and/or competitive factors.
Forward‐looking statements necessarily involve assumptions, risks and uncertainties, certain of which are beyond the Company’s control. These forward‐looking statements are qualified in their entirety by cautionary statements and risk factor disclosure contained in filings made by the Company with the Canadian securities regulators, including the Company’s financial statements, related MD&A and Annual Information Form for the financial year ended August 31, 2021 and its interim financial statements and related MD&A for the three and six months ended February 28, 2022, all filed with the securities regulatory authorities in all provinces and territories of Canada, except Québec, and available under the Company’s profile at www.sedar.com. The risk factors are not exhaustive of the factors that may affect the Company’s forward‐looking statements. The Company’s forward‐looking statements are based on the applicable assumptions and factors management considers reasonable as of the date hereof, based on the information available to management of the Company at such time. The Company does not assume any obligation to update forward‐looking statements if circumstances or management’s beliefs, expectations or opinions should change other than as required by applicable securities laws. There can be no assurance that forward‐looking statements will prove to be accurate, and actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward‐looking statements. Accordingly, undue reliance should not be placed on forward‐looking statements.
SOURCE Numinus Wellness Inc.